Honokiol thwarts gastric tumor growth and peritoneal dissemination by inhibiting Tpl2 in an orthotopic model

Carcinogenesis

Volumn 34, Issue 11, 2013, Pages 2568-2579

  Pan, Hung Chuan ^a,b,c   Lai, De Wei ^c   Lan, Keng Hsin ^a,d   Shen, Chin Chang ^e   Wu, Sheng Mao ^c   Chiu, Chien Shan ^b,c   Wang, Keh Bin ^f   Sheu, Meei Ling ^b,c  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^c NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^d TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^e INSTITUTE OF NUCLEAR ENERGY RESEARCH   (Taiwan)

^f KUANG TIEN GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN BETA; CYTOKERATIN 18; HONOKIOL; METHYLNITRONITROSOGUANIDINE; PEPTIDES AND PROTEINS; PROTEIN TUMOR PROGRESSION LOCUS 2; TRANSCRIPTION FACTOR SNAIL; UNCLASSIFIED DRUG; UVOMORULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; DOWN REGULATION; ENDOPLASMIC RETICULUM STRESS; ENDOTHELIUM CELL; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PERITONEUM METASTASIS; PRIORITY JOURNAL; STOMACH TUMOR; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BIPHENYL COMPOUNDS; BLOTTING, WESTERN; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOPRECIPITATION; LIGNANS; LUCIFERASES; MALE; MAP KINASE KINASE KINASES; MICE; MICE, INBRED BALB C; MICE, NUDE; PERITONEAL NEOPLASMS; PHYTOTHERAPY; PROTO-ONCOGENE PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STOMACH NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 84886992745     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgt243     Document Type: Article

References (61)

1. De,C.B.et al. (2013) Regulatory networks defining EMT during cancer initiation and progression. Nat. Rev. Cancer, 13, 97-110.
2. Peinado,H.et al. (2007) Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat. Rev. Cancer, 7, 415-428.
3. Yonemura,Y.et al. (1996) Effects of intraoperative chemohyperthermia in patients with gastric cancer with peritoneal dissemination. Surgery, 119, 437-444.
4. Gao,D.et al. (2012) Microenvironmental regulation of epithelial-mesenchymal transitions in cancer. Cancer Res., 72, 4883-4889.
5. Castro,A.C.et al. (2007) Slug is overexpressed in gastric carcinomas and may act synergistically with SIP1 and Snail in the down-regulation of E-cadherin. J. Pathol., 211, 507-515.
6. Rosivatz,E.et al. (2002) Differential expression of the epithelial-mesenchymal transition regulators snail, SIP1, and twist in gastric cancer. Am. J. Pathol., 161, 1881-1891.
7. Katoh,M.et al. (2009) Integrative genomic analyses of ZEB2: transcriptional regulation of ZEB2 based on SMADs, ETS1, HIF1alpha, POU/OCT, and NF-kappaB. Int. J. Oncol., 34, 1737-1742.
8. Venkov,C.D.et al. (2007) A proximal activator of transcription in epithelial-mesenchymal transition. J. Clin. Invest., 117, 482-491.
9. Strippoli,R.et al. (2010) p38 maintains E-cadherin expression by modulating TAK1-NF-kappa B during epithelial-to-mesenchymal transition. J. Cell Sci., 123(Pt 24), 4321-4331.
10. Liu,W.F.et al. (2012) CD146 Expression correlates with epithelial-mesenchymal transition markers and a poor prognosis in gastric cancer. Int. J. Mol. Sci., 13, 6399-6406.
11. Zhong,X.Y.et al. (2008) Positive association of up-regulated Cripto-1 and down-regulated E-cadherin with tumour progression and poor prognosis in gastric cancer. Histopathology, 52, 560-568.
12. Vougioukalaki,M.et al. (2011) Tpl2 kinase signal transduction in inflammation and cancer. Cancer Lett., 304, 80-89.
13. Ohara,R.et al. (1995) Identification of the cells expressing cot proto-oncogene mRNA. J. Cell Sci., 108(Pt 1), 97-103.
14. Krcova,Z.et al. (2008) Tpl-2/Cot and COX-2 in breast cancer. Biomed. Pap. Med. Fac. Univ. Palacky. Olomouc. Czech. Repub., 152, 21-25.
15. Sourvinos,G.et al. (1999) Overexpression of the Tpl-2/Cot oncogene in human breast cancer. Oncogene, 18, 4968-4973.
16. Risco,A.et al. (2012) p38γ and p38δ kinases regulate the Toll-like receptor 4 (TLR4)-induced cytokine production by controlling ERK1/2 protein kinase pathway activation. Proc. Natl Acad. Sci. USA, 109, 11200-11205.
17. Eliopoulos,A.G.et al. (2003) Tpl2 transduces CD40 and TNF signals that activate ERK and regulates IgE induction by CD40. EMBO J., 22, 3855-3864.
18. Liu,Z.et al. (2012) Telomerase reverse transcriptase promotes epithelial-mesenchymal transition and stem cell-like traits in cancer cells. Oncogene, 8, doi: 10.1038/onc.2012.441.
19. Shinto,O.et al. (2010) Inhibitory effect of a TGFbeta receptor type-I inhibitor, Ki26894, on invasiveness of scirrhous gastric cancer cells. Br. J. Cancer, 102, 844-851.
20. Ono,Y.et al. (2012) Direct inhibition of the transforming growth factor-β pathway by protein-bound polysaccharide through inactivation of Smad2 signaling. Cancer Sci., 103, 317-324.
21. Lee,S.H.et al. (2007) Chemical carcinogen, N-methyl-N'-nitro-Nnitrosoguanidine, is a specific activator of oncogenic Ras. Cell Cycle, 6, 1257-1264.
22. Koliaraki,V.et al. (2012) Tpl2 regulates intestinal myofibroblast HGF release to suppress colitis-associated tumorigenesis. J. Clin. Invest., 122, 4231-4242.
23. Decicco-Skinner,K.L.et al. (2011) Loss of tumor progression locus 2 (tpl2) enhances tumorigenesis and inflammation in two-stage skin carcinogenesis. Oncogene, 30, 389-397.
24. Garcia,A.et al. (2008) Honokiol suppresses survival signals mediated by Ras-dependent phospholipase D activity in human cancer cells. Clin. Cancer Res., 14, 4267-4274.
25. Fried,L.E.et al. (2009) Honokiol, a multifunctional antiangiogenic and antitumor agent. Antioxid. Redox Signal., 11, 1139-1148.
26. Funa,N.S.et al. (2008) Shb gene knockdown increases the susceptibility of SVR endothelial tumor cells to apoptotic stimuli in vitro and in vivo. J. Invest. Dermatol., 128, 710-716.
27. Tsai,T.H.et al. (1994) Pharmacokinetics of honokiol after intravenous administration in rats assessed using high-performance liquid chromatography. J. Chromatogr. B. Biomed. Appl., 655, 41-45.
28. Sheu,M.L.et al. (2007) Honokiol induces calpain-mediated glucose-regulated protein-94 cleavage and apoptosis in human gastric cancer cells and reduces tumor growth. PLoS One, 2, e1096.
29. Liu,S.H.et al. (2010) Honokiol inhibits gastric tumourigenesis by activation of 15-lipoxygenase-1 and consequent inhibition of peroxisome proliferator-activated receptor-gamma and COX-2-dependent signals. Br. J. Pharmacol., 160, 1963-1972.
30. Liu,S.H.et al. (2012) Calpain/SHP-1 interaction by honokiol dampening peritoneal dissemination of gastric cancer in nu/nu mice. PLoS One, 7, e43711.
31. Sheu,M.L.et al. (2008) Inhibition of NADPH oxidase-related oxidative stress-triggered signaling by honokiol suppresses high glucoseinduced human endothelial cell apoptosis. Free Radic. Biol. Med., 44, 2043-2050.
32. Chiang,C.K.et al. (2006) Honokiol, a small molecular weight natural product, alleviates experimental mesangial proliferative glomerulonephritis. Kidney Int., 70, 682-689.
33. Chiang,C.K.et al. (2011) Honokiol ameliorates renal fibrosis by inhibiting extracellular matrix and pro-inflammatory factors in vivo and in vitro. Br. J. Pharmacol., 163, 586-597.
34. Liu,S.H.et al. (2013) Advanced glycation end product N(epsilon)-carboxymethyllysine induces endothelial cell injury: the involvement of SHP-1-regulated VEGFR-2 dephosphorylation. J. Pathol., 230, 215-227.
35. Lee,K.M.et al. (2009) Tpl2 is a key mediator of arsenite-induced signal transduction. Cancer Res., 69, 8043-8049.
36. Li,Y.L.et al. (2009) In vitro selection of adenine-dependent ribozyme against Tpl2/Cot oncogene. FEBS J., 276, 303-314.
37. Perfield,J.W. II et al. (2011) Tumor progression locus 2 (TPL2) regulates obesity-associated inflammation and insulin resistance. Diabetes, 60, 1168-1176.
38. Van Acker,G.J. et al. (2007) Tumor progression locus-2 is a critical regulator of pancreatic and lung inflammation during acute pancreatitis. J. Biol. Chem., 282, 22140-22149.
39. Jeong,J.H.et al. (2011) TPL2/COT/MAP3K8 (TPL2) activation promotes androgen depletion-independent (ADI) prostate cancer growth. PLoS One, 6, e16205.
40. Tsatsanis,C.et al. (2008) Tpl2 and ERK transduce antiproliferative T cell receptor signals and inhibit transformation of chronically stimulated T cells. Proc. Natl Acad. Sci. USA, 105, 2987-2992.
41. Christoforidou,A.V.et al. (2004) Expression of the Tpl2/Cot oncogene in human T-cell neoplasias. Mol. Cancer, 3, 34.
42. Schwitalla,S.et al. (2013) Loss of p53 in enterocytes generates an inflammatory microenvironment enabling invasion and lymph node metastasis of carcinogen-induced colorectal tumors. Cancer Cell, 23, 93-106.
43. Ellis,L.M.et al. (2008) VEGF-targeted therapy: mechanisms of antitumour activity. Nat. Rev. Cancer, 8, 579-591.
44. Sennino,B.et al. (2012) Controlling escape from angiogenesis inhibitors. Nat. Rev. Cancer, 12, 699-709.
45. Ferrara,N. (2002) VEGF and the quest for tumour angiogenesis factors. Nat. Rev. Cancer, 2, 795-803.
46. Harper,S.J.et al. (2008) VEGF-A splicing: the key to anti-angiogenic therapeutics? Nat. Rev. Cancer, 8, 880-887.
47. Harris,A.L. (2002) Hypoxia-a key regulatory factor in tumour growth. Nat. Rev. Cancer, 2, 38-47.
48. Zhang,D.et al. (2010) β2-adrenergic antagonists suppress pancreatic cancer cell invasion by inhibiting CREB, NFκB and AP-1. Cancer Biol. Ther., 10, 19-29.
49. Min,Y.et al. (2011) C/EBP-δ regulates VEGF-C autocrine signaling in lymphangiogenesis and metastasis of lung cancer through HIF-1α. Oncogene, 30, 4901-4909.
50. Kögel,D.et al. (2006) Induction of transcription factor CEBP homology protein mediates hypoglycaemia-induced necrotic cell death in human neuroblastoma cells. J. Neurochem., 99, 952-964.
51. Chiariello,M.et al. (2000) Multiple mitogen-activated protein kinase signaling pathways connect the cot oncoprotein to the c-jun promoter and to cellular transformation. Mol. Cell. Biol., 20, 1747-1758.
52. Serebrennikova,O.B.et al. (2012) Tpl2 ablation promotes intestinal inflammation and tumorigenesis in Apcmin mice by inhibiting IL-10 secretion and regulatory T-cell generation. Proc. Natl Acad. Sci. USA, 109, E1082-E1091.
53. Dumitru,C.D.et al. (2000) TNF-alpha induction by LPS is regulated posttranscriptionally via a Tpl2/ERK-dependent pathway. Cell, 103, 1071-1083.
54. Johannessen,C.M.et al. (2010) COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature, 468, 968-972.
55. Kim,T.et al. (2010) Inhibition of mutated BRAF in melanoma. N. Engl. J. Med., 363, 2261; author reply 2261-2261; author reply 2262.
56. Davies,H.et al. (2002) Mutations of the BRAF gene in human cancer. Nature, 417, 949-954.
57. Knight,D.A.et al. (2013) Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J. Clin. Invest., 123, 1371-1381.
58. Hetz,C. (2012) The unfolded protein response: controlling cell fate decisions under ER stress and beyond. Nat. Rev. Mol. Cell Biol., 13, 89-102.
59. Kim,I.et al. (2008) Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities. Nat. Rev. Drug Discov., 7, 1013-1030.
60. Verfaillie,T.et al. (2013) Targeting ER stress induced apoptosis and inflammation in cancer. Cancer Lett., 332, 249-264.
61. Banerjee,A.et al. (2011) Unfolded protein response is required in nu/nu mice microvasculature for treating breast tumor with tunicamycin. J. Biol. Chem., 286, 29127-29138.